Brandon Couillard
Stock Analyst at Wells Fargo
(3.41)
# 537
Out of 5,182 analysts
168
Total ratings
44.57%
Success rate
5.04%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLLN BillionToOne | Maintains: Equal-Weight | $110 → $90 | $91.98 | -2.15% | 2 | Mar 5, 2026 | |
| NTRA Natera | Maintains: Equal-Weight | $205 → $215 | $210.83 | +1.98% | 4 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $116.92 | +41.12% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $119.77 | +50.29% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $17.92 | +17.19% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.77 | +25.79% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $92.84 | +34.64% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $8.00 | +75.00% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $318.53 | +11.45% | 8 | Feb 11, 2026 | |
| WGS GeneDx Holdings | Upgrades: Overweight | $155 | $65.59 | +136.32% | 7 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $76 | $55.21 | +37.66% | 3 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $83 → $94 | $93.97 | +0.03% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $90.40 | +21.68% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $503.46 | +34.07% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,322.76 | +9.62% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.11 | +44.69% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $240 | $196.19 | +22.33% | 5 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $38.25 | +43.79% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $281.15 | +20.93% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $277.00 | +22.74% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $176.83 | +47.03% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $75.53 | +5.92% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $26.66 | -13.73% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $3.13 | +315.34% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.09 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.21 | +397.74% | 2 | Oct 13, 2017 |
BillionToOne
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $110 → $90
Current: $91.98
Upside: -2.15%
Natera
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $205 → $215
Current: $210.83
Upside: +1.98%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $116.92
Upside: +41.12%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $119.77
Upside: +50.29%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $17.92
Upside: +17.19%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.77
Upside: +25.79%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $92.84
Upside: +34.64%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $8.00
Upside: +75.00%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $318.53
Upside: +11.45%
GeneDx Holdings
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $65.59
Upside: +136.32%
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $55.21
Upside: +37.66%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $93.97
Upside: +0.03%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $90.40
Upside: +21.68%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $503.46
Upside: +34.07%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,322.76
Upside: +9.62%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.11
Upside: +44.69%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $230 → $240
Current: $196.19
Upside: +22.33%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $38.25
Upside: +43.79%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $281.15
Upside: +20.93%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $277.00
Upside: +22.74%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $176.83
Upside: +47.03%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $75.53
Upside: +5.92%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $26.66
Upside: -13.73%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $3.13
Upside: +315.34%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.09
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.21
Upside: +397.74%